This study is a first to demonstrate that inhibition of Kpnβ1 is an effective way to enhance the anti-cancer effects of cisplatin, and that both cisplatin sensitive, HeLa, and the more resistant, SiHa cervical cancer cells were responsive to this treatment. This evidence concerns the gene KPNB1 and cervical carcinoma.